Compare PRE & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRE | RCEL |
|---|---|---|
| Founded | 2014 | N/A |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.5M | 306.5M |
| IPO Year | 2021 | 2018 |
| Metric | PRE | RCEL |
|---|---|---|
| Price | $23.60 | $9.88 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $30.50 | $7.88 |
| AVG Volume (30 Days) | 278.6K | ★ 360.8K |
| Earning Date | 06-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.20 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $71,610,000.00 |
| Revenue This Year | $108.69 | $17.17 |
| Revenue Next Year | $58.68 | $49.82 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.45 |
| 52 Week Low | $9.29 | $3.22 |
| 52 Week High | $27.24 | $11.39 |
| Indicator | PRE | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 54.71 | 59.18 |
| Support Level | $17.49 | $3.64 |
| Resistance Level | $27.24 | $10.77 |
| Average True Range (ATR) | 1.69 | 0.55 |
| MACD | -0.07 | -0.19 |
| Stochastic Oscillator | 63.62 | 15.02 |
Prenetics Global Ltd is a consumer health and wellness company offering nutrition and longevity products through its flagship brand, IM8. It offers science-backed daily nutrition and longevity products distributed directly to consumers across multiple countries. The company's products are developed with scientific input and are subject to third-party quality certifications.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.